<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903041</url>
  </required_header>
  <id_info>
    <org_study_id>ACCR</org_study_id>
    <nct_id>NCT04903041</nct_id>
  </id_info>
  <brief_title>A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).</brief_title>
  <official_title>A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaime Marino</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apollo Hospitals Enterprise Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott Diagnostics Division</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease is the leading cause of mortality globally. In India cardiovascular&#xD;
      disease leads to death a decade earlier than in western countries. In the past 20 years&#xD;
      awareness and classic risk factors and statins have been the main improvements. However, all&#xD;
      these factors have not decreased the cardiovascular disease burden. One reason may be because&#xD;
      all of the current assessments for cardiac risk are correlants to disease and none are&#xD;
      specific to cardiac myocyte status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Development of high-sensitivity assays for cardiac troponin I (hs-TnI) has enhanced the&#xD;
      ability to detect low circulating levels of cardiac troponins, which are often present in&#xD;
      individuals with common cardiac conditions and risk factors who have not manifested clinical&#xD;
      cardiovascular disease (CVD). Lowering the detection threshold of troponin assays has&#xD;
      expanded the potential use of cardiac troponins from a diagnostic tool in the setting of&#xD;
      acute coronary syndrome to a biomarker for risk stratification in individuals without known&#xD;
      CVD. Detectable levels of cardiac troponins have been associated with increased incidence of&#xD;
      coronary heart disease (CHD), heart failure (HF), and cardiovascular mortality in&#xD;
      community-based studies.&#xD;
&#xD;
      Traditional cardiovascular risk prediction does not identify everyone who will develop&#xD;
      cardiovascular disease with up to 50% of individuals having none or only one risk factor at&#xD;
      the time of diagnosis. Although traditional risk estimations perform moderately well, there&#xD;
      remain significant limitations in their use in the prevention of cardiovascular disease&#xD;
      especially at an individual level. At an individual level, the clinician not only needs to&#xD;
      correctly identify those at increased risk, but also weigh up the importance of each risk&#xD;
      factor and determine who needs medical therapy in addition to lifestyle advice Many risk&#xD;
      estimation systems in existence are based on a core set of cardiovascular risk factors and&#xD;
      based on participants either selected randomly from the general population or those attending&#xD;
      their general practitioner. All these risk scoring systems show a good level of&#xD;
      discrimination, for cardiovascular events, with the area under the receiving operator curve&#xD;
      ranging from 0.73 to 0.82. However, adopting these risk scoring systems to guide current&#xD;
      clinical practice has limitations. First, most of these scoring systems, except QRISK1 and&#xD;
      QRISK2 have been developed from old prospective cohorts with participants recruited in the&#xD;
      1980's and 1990's Second, applying risk estimation scores to regions with different rates of&#xD;
      baseline rates of cardiovascular disease will lead to either under- or over-estimation of&#xD;
      risk: a result of mis-calibration. Third, the value of incorporating new risk factors&#xD;
      including biomarkers such as high-sensitivity C reactive protein has been disappointing in&#xD;
      improving discrimination, with age and sex alone contributing to 0.70 of the area under the&#xD;
      receiver operating curve statistic. None of these risk estimation scores, to date,&#xD;
      incorporate a direct measure of cardiac injury such as cardiac troponin and its potential&#xD;
      role in guiding primary prevention in a contemporaneous population remains uncertain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Anticipated">September 12, 2030</completion_date>
  <primary_completion_date type="Anticipated">September 12, 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Evaluate the hsTnI categorical CVD risk model with the Apollo Healthcare system in subjects attending the Preventive Health Checkups.</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Number of individuals classified as high, moderate, low risk based on the pre-defined cut-offs of high-sensitivity troponin I.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implementation of recommendation for the low, moderate and high risk in subjects and monitoring the outcome in the cardiac registry database.</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Number of individuals that follows the cardiovascular risk stratification algorithm: lifestyle consultation, treatment of underlying conditions such as hypertension, diabetes, hyperlipidemia as well as ECG, stress test echocardiography recommendations and number of individuals experiencing the adverse cardiovascular outcomes per cardiovascular risk category.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Optimize the use of hsTnI risk categories by clinicians</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Estimate the longitudinal changes of the number of clinicians that recommend the following based on the cardiovascular risk stratification algorithm: lifestyle consultation, treatment of underlying conditions such as hypertension, diabetes, hyperlipidemia as well as ECG, stress test and echocardiography recommendations.</description>
  </other_outcome>
  <enrollment type="Anticipated">300000</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects undergoing health checks at Apollo Group of hospitals in Hyderabad, Chennai,&#xD;
        Bangalore, Mumbai, Kolkata and New Delhi.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All men and women above the age of 18 years&#xD;
&#xD;
          2. Lipid profiles ordered&#xD;
&#xD;
          3. HbA1c ordered&#xD;
&#xD;
          4. Creatinine ordered&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Non-consenting subjects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pratap C Reddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apollo Hopsitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hari Prasad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apollo Hospitals Enterprise Limited</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abraham Oomman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apollo Hospitals Enterprise Limited</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Padma Madala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apollo Hospitals Enterprise Limited</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaganathan Sickan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Agim Beshiri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>S Danalakshmi, MD</last_name>
    <phone>91 - 0884 - 2302600</phone>
    <email>info_kkd@apollohospitals.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Udhaya, MD</last_name>
    <phone>91 - 0884 - 2302600</phone>
    <email>info_kkd@apollohospitals.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parineetha, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S Danalakshmi, MD</last_name>
      <phone>91 - 0884 - 2302600</phone>
      <email>info_kkd@apollohospitals.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sahasini Domalapally, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E M Khan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaudhari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abha Gupta, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Lankeit M, Jiménez D, Kostrubiec M, Dellas C, Hasenfuss G, Pruszczyk P, Konstantinides S. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation. 2011 Dec 13;124(24):2716-24. doi: 10.1161/CIRCULATIONAHA.111.051177. Epub 2011 Nov 14.</citation>
    <PMID>22082681</PMID>
  </reference>
  <reference>
    <citation>Xue Y, Clopton P, Peacock WF, Maisel AS. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail. 2011 Jan;13(1):37-42. doi: 10.1093/eurjhf/hfq210. Epub 2010 Dec 13.</citation>
    <PMID>21149316</PMID>
  </reference>
  <reference>
    <citation>Røsjø H, Varpula M, Hagve TA, Karlsson S, Ruokonen E, Pettilä V, Omland T; FINNSEPSIS Study Group. Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcome. Intensive Care Med. 2011 Jan;37(1):77-85. doi: 10.1007/s00134-010-2051-x. Epub 2010 Oct 12.</citation>
    <PMID>20938765</PMID>
  </reference>
  <reference>
    <citation>Afonso L, Bandaru H, Rathod A, Badheka A, Ali Kizilbash M, Zmily H, Jacobsen G, Chattahi J, Mohamad T, Koneru J, Flack J, Weaver WD. Prevalence, determinants, and clinical significance of cardiac troponin-I elevation in individuals admitted for a hypertensive emergency. J Clin Hypertens (Greenwich). 2011 Aug;13(8):551-6. doi: 10.1111/j.1751-7176.2011.00476.x. Epub 2011 Jun 27.</citation>
    <PMID>21806764</PMID>
  </reference>
  <reference>
    <citation>Høiseth AD, Neukamm A, Karlsson BD, Omland T, Brekke PH, Søyseth V. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2011 Sep;66(9):775-81. doi: 10.1136/thx.2010.153122. Epub 2011 Jun 8.</citation>
    <PMID>21653926</PMID>
  </reference>
  <reference>
    <citation>de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010 Dec 8;304(22):2503-12. doi: 10.1001/jama.2010.1768. Erratum in: JAMA. 2011 Mar 23;305(12):1200.</citation>
    <PMID>21139111</PMID>
  </reference>
  <reference>
    <citation>deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010 Dec 8;304(22):2494-502. doi: 10.1001/jama.2010.1708. Epub 2010 Nov 15.</citation>
    <PMID>21078811</PMID>
  </reference>
  <reference>
    <citation>Meune C, Reichlin T, Irfan A, Schaub N, Twerenbold R, Meissner J, Reiter M, Lüthi A, Haaf P, Balmelli C, Drexler B, Winkler K, Hochholzer W, Osswald S, Mueller C. How safe is the outpatient management of patients with acute chest pain and mildly increased cardiac troponin concentrations? Clin Chem. 2012 May;58(5):916-24. doi: 10.1373/clinchem.2011.178053. Epub 2012 Mar 12.</citation>
    <PMID>22410086</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Abbott Diagnostics Division</investigator_affiliation>
    <investigator_full_name>Jaime Marino</investigator_full_name>
    <investigator_title>Sr Medical Affairs Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

